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EXECUTIVE SUMMARY
The Commission to Study the Use of Pharmaceuticals in Long-Term Care Settings
was created by Resolves 1997, chapter 71. Commission membership included
representatives of long-term care recipients, long-term care pharmacists, long-term care
pharmacy providers, a physician and a nurse with long-term care experience, 2 members of
the Joint Standing Committee on Health and Human Services and one other legislator, and
a pharmacist or designee from the Department of Human Services with expertise in
Medicaid reimbursement.  The Commission was directed to examine the use of
pharmaceuticals in long-term care settings.  The six topics the Commission was directed to
examine and the findings and recommendations with regard to each are as follows:
· Resolve Issue #1:  Examine the reimbursement formulas given to long-term
care pharmacy providers including fees for service and capitation rates for
services
The Commission makes no recommendations on the issue of reimbursement
formulas for long-term care pharmacy providers, but asks the Legislature to consider the
issues presented in the full report.
· Resolve issue #2:  Examine the payment of a consultant fee to providers of
long-term care pharmacy services and whether there is an inherent conflict of
interest between providing consulting and dispensing services
The Commission recommends that a system of monitoring be put into place to
ensure that long-term care facilities are complying with federal law by entering into
appropriate contracts with consultant pharmacists.  Contracts must provide for proper and
adequate reimbursement for the services of the consultant pharmacist, to guard against
inappropriate activity under which a pharmacy offers to provide the consulting service for
unreasonably low compensation in order to obtain the dispensing services contract and
make up for the losses through drug costs and filling fees.
The Commission recommends that Maine enact an anti-kickback statute similar to
federal law that prohibits fraudulent business practices.
The Commission urges long-term care facilities staff and their residents to educate
themselves about the qualifications and services offered by consultant pharmacists and
about the potential for improved outcomes, quality assurance and decreased
pharmaceuticals costs from consultant pharmacists who offer a quality of service above
and beyond the minimum requirements.  The Commission supports a market-driven
philosophy for the provision of consultant services and encourages consultant pharmacists
to offer the highest quality of services.
· Resolve Issue #3:  Examine the determination of new rules pertaining to
dispensing pharmaceuticals in long-term care facilities, such as minimum
supply, and fees charged for the same medication dispensed in the same month
The Commission recommends that the Department of Human Services periodically
review its guidelines for dispensing medications for a Medicaid resident, with
consideration given for the changing needs of physicians and staff to manage acute-care
residents.  Those residents may have multiple changes in medication therapies over short
periods of time.
The Commission recommends that long-term care facilities be made aware of
problems and possible solutions to problems relating to minimum supply, and that they
work with all disciplines to ensure that the most reasonable, cost-effective dispensing
practices are offered and maintained.
· Resolve Issue #4:  Examine conflict of interest created by concurrent
ownership of long-term care facilities and of pharmacies or other related health
care providers that provide services to residents
The Commission recommends that the Department of Human Services review the
current prohibition against paying a filling fee to pharmacies that own and provide services
to nursing homes, to determine whether the current economic situation justifies a
continuation of the prohibition.
· Resolve Issue #5:  Examine whether there is a practice of overprescribing in
long-term care facilities
The Commission was unable to determine whether there is a practice of
overprescribing in long-term care facilities in Maine.  The Commission does recommend
the development of pharmaceutical care guidelines for geriatric residents in long-term care
facilities.  Once developed, these guidelines would offer geriatric-focused clinical
information, assist in providing appropriate pharmaceutical care, and recommend
acceptable and unacceptable drug products by clinical indication.  Such guidelines can be a
valuable tool in enhancing the quality of care and improving outcomes while providing
more cost-effective drug therapy.
· Resolve Issue #6:  Examine whether there are potential cost savings and other
benefits from more efficient patterns for stocking standard, nonchargeable
medical supplies
The requirement to provide house stock items is an issue that must be enforced on
the nursing home level.  Long-term care pharmacy providers should be aware that these
items are not billable to Medicaid residents.  Private paying residents should be reminded
of their right to purchase these items from a pharmacy of their choice.
Report of the Commission on
Pharmaceuticals in Long-term Care Settings Page 5
INTRODUCTION
The Commission to Study the Use of Pharmaceuticals in Long-Term Care Settings
was created by Resolves 1997, chapter 71. Commission membership included
representatives of long-term care recipients, long-term care pharmacists, long-term care
pharmacy providers, a physician and a nurse with long-term care experience, 2 members of
the Joint Standing Committee on Health and Human Services and one other legislator, and
a pharmacist or designee from the Department of Human Services with expertise in
Medicaid reimbursement.  The Commission was directed to examine the use of
pharmaceuticals in long-term care settings, and to examine specifically:
· Reimbursement formulas for long-term care pharmacy providers;
 
· Consulting fees to providers of long-term care pharmacy services and whether
a conflict of interest exists between providing consulting and dispensing
pharmacy services;
 
· Rules for dispensing of pharmaceuticals in long-term care facilities;
 
· Conflict of interest created by concurrent ownership of long-term care facilities
and pharmacies or other related health care providers;
 
· Possible overprescribing in long-term care facilities;  and
 
· The potential for cost savings and other benefits from more efficient patterns of
stocking standard, nonchargeable medical supplies.
 The Commission was convened on January 5, 1998 and was asked to expedite its study
and complete its work by January 23, 1998.  At the first meeting of the Commission,
members elected Michael J. Fiori as Commission chair.
During its two January meetings, commission members discussed the various
issues listed in the Resolve creating the study.  Through those discussions, members
gained a greater understanding of the legal and practical considerations governing each
issue and developed some specific recommendations.  Following its last meeting, the
Commission prepared this report that, after review be commission members, was issued in
March of 1998.
This report is a summary of Commission discussions and recommendations,
prepared by Michael Fiori, Commission Chair, with approval of the full Commission.
Attached as appendices are supporting materials.
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REIMBURSEMENT FORMULAS
· Resolve Issue #1:  Examine the reimbursement formulas given to long-term
care pharmacy providers including fees for service and capitation rates for
services
Non-Medicaid reimbursement.
The level of pharmacy services reimbursement by third-party  payors (payors other
than Medicaid) is driven by the market.  Generally, the third party pharmacy benefit
manager “dictates” the reimbursement level to the pharmacy or pharmacist.
There is controversy in the industry over the low rates of reimbursement offered by
third party plans.  Prescription department margins have dropped significantly in the past 5
to 10 years, jeopardizing the sustainability of many pharmacies.  As a consequence, many
pharmacies have had to increase their volume of business in order to survive.
Medicaid reimbursement
Medicaid reimbursement includes a formula for reimbursement for the drugs
themselves and a $3.35 filling fee.  The Medicaid filling fee has not been increased in
approximately 8 years.
While several Commission members agreed that the pharmacist deserved an
increase in the filling fee, it is recognized that a fee increase would require approval from
the Health Care Financing Administration (HCFA) if the proposed increase were “outside
the prevailing market.”
The State of Maine prescription filling fee/formula is currently lower than
approximately half of the states.
Adding to the concern about the filling fee is the fact that Maine has recently
begun deducting a 25-cent “processing fee” from the $3.35 filling fee, which nets to the
pharmacy a $3.10 filling fee.  The legality of this deduction is currently being challenged
by at least one large chain pharmacy organization in Maine and several pharmacy
associations. The federal Health Care Financing Administration has not issued a final
ruling on the challenge, but has preliminarily stated that the deduction cannot be termed an
“administrative fee” or other such terminology.
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Differential Packaging Costs
Long-term care facilities utilize “unit-dose” packaging, usually some form of
“blister-pack” packaging.  This makes it possible to return unused medications for a partial
credit to the Medicaid program or private paying patient.  This type of packaging also
improves safety and nursing home outcomes by ensuring that the proper dosage is given.
Unit-dose packaging uses more expensive material and requires more of the
pharmacist’s or technician’s time than the traditional “bottle and vial” packaging  used in
retail pharmacies.  The preparation of the medications involves wrapping each tablet or
capsule in individual blisters, providing delivery reports, providing narcotic count sheets
and breaking tablets for unusual doses.  It has been estimated by several long-term care
pharmacy providers that the process requires 2 to 3 times more time to prepare, but there
is no consideration in the Maine program for this increased cost to the pharmacy
providers.  They are paid the same fee that is given for traditional retail pharmacy
packaging.  Some other states do have a fee differential for unit-dose packaging.
The Department of Human Services recently adopted a rule allowing for higher
rates of reimbursement to a pharmacy that uses a unit-dose dispensing system that results
in no return of drugs.  Those pharmacies will receive a 2.5% higher rate of reimbursement
as an incentive to initiate such a system and to defray the added costs.  The current
reimbursement cap is average wholesale price (AWP) minus 10%;   under this program,
the cap is AWP minus 7.5%.  The Department believes that the savings to the State from
not having to process returns or prepare the financial reporting will offset the added
expense.  Cost savings have not yet been determined for the project, which began in the
spring of 1997.  (See Appendix B, section 80.09-A of Chapter II of the Maine Medical
Assistance Manual)
Capitation rates
Capitation rates and formulas were briefly discussed, but it was concluded that
since the reimbursement is market-driven no company is now precluded from offering
capitation or using capitation rates or formulas.
· Recommendations/Considerations:  The Commission makes no
recommendations on the issue of reimbursement formulas for long-term care
pharmacy providers, but asks the Legislature to consider the issues presented
in the discussion.
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CONSULTING PHARMACISTS, FEES, POTENTIAL CONFLICTS
· Resolve issue #2:  Examine the payment of a consultant fee to providers of
long-term care pharmacy services and whether there is an inherent conflict of
interest between providing consulting and dispensing services
Commission members decided that this issue involves 3 areas to be considered:
whether there is an inherent conflict of interest when pharmacies provide both consulting
and dispensing services; the reimbursement rates and practices of consultant pharmacists
in Maine; and guidelines and criteria for consultant pharmacists to long-term care settings.
Federal requirements for consultant pharmacists
Federal Medicaid law requires long-term care facilities to employ the services of a
licensed pharmacist to review drug regimens and perform other designated services.  42
Code of Federal Regulations, section 483.60.  These consultant pharmacists practice
under federal and state regulations.  These regulations are fairly general in nature, but
require that a pharmacist:
1) Be hired under a written contract as a consultant to the facility;
2) Perform routine inspections of the pharmaceuticals storage areas;
3) Perform drug-regimen reviews of the residents’ charts;
4) Check emergency and starter dose boxes;
5) Review medication administration techniques;
6) Provide in-services, attend policy meetings, etc.;  and
7) Provide written reports of their activities, findings and recommendations.
The level of service required of the consultant pharmacist is determined by the particular
licensing status of the facility, e.g., skilled nursing facility, intermediate care nursing
facility and boarding care.
Reimbursement to consultant pharmacists
Payment to consultant pharmacists is often negotiable, and covers 2 types of
services  -- the “special services” which relate to the care of an individual resident, and
“routine services” relating to the facility generally, e.g. review of medication storage areas
and in-service education.
Federal law requires a monthly review by a licensed pharmacist of the drug-care
regimen of each patient.  Maine’s Medicaid reimbursement principles provide for a special
services allowance of up to $2.50 per resident review per month for each review
performed in addition to any pharmacist consultant fees.  This “cognitive services fee” is
essentially a pass-through for the nursing home in the per diem rate.
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Payment for services other than the drug-regimen review is more controversial.
Most larger providers of these services charge approximately a $1.00 per resident per
month “consulting fee” for all other services performed.
For Medicaid residents, facilities are reimbursed a certain rate per diem for which
the total care of the resident is covered.  This includes dietary, social services, nursing,
room rate and activities.  Out of these per diem monies come reimbursement to the
consultant pharmacist for services other than drug-regimen review.
In recent years, some facilities have negotiated with some pharmacies to provide
the entire consultant pharmacist package, including drug-regimen review, for the $2.50
drug-regimen review special service fee.  In these instances, there is no other
reimbursement to the consultant pharmacist.  In essence, the facility is paying no fee for
routine service by the consultant pharmacist, e.g., in-service education, physical review of
medication stations and med carts, and maintenance of emergency drug and starter-does
kits.  This allows the facility to retain more of its per diem monies to be used for other
services.
This practice by both facility and pharmacy may be in violation of federal law.  The
federal anti-kickback law prohibits a person from offering or receiving remuneration in
exchange for ordering, recommending, arranging or referring a service covered by
Medicare or Medicaid.  42 USC §1320a-7b.  According to a 1995 paper presented to the
American Society of Consultant Pharmacists by Arthur N. Lerner, Esq,  provision of
consulting services to long-term care facilities at no or reduced charge in consideration for
status as preferred dispensing pharmacy to inpatients of the facility could be found to
violate the federal anti-kickback law.
Facilities defend the practice by stating that they are paying a $2.50 consultant
pharmacist fee per resident per month and long-term care pharmacy providers use this as a
competitive edge to induce contracts from facilities.
Current hourly rates for pharmacists in Maine, without benefits, range from $27 -
$32 per hour.  The amount of time a consultant pharmacist spends in a facility doing
required work varies considerably among facilities and professionals, but 6 to 12 hours per
month for a facility with 50 to 100 residents is a reasonable estimate.
In recent years, the Office of Inspector General (OIG) of the federal Department of
Health and Human Services has adopted “safe harbor” regulations to further define the
scope of the federal Medicare and Medicaid fraud and abuse statutes.  These provisions
were first published in the Federal Register on November 5, 1992 in interim final form.
Since that time, there have been many business practices of pharmacists that have received
increased scrutiny by federal and state watchdog agencies.
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The American Society of Consultant Pharmacists has issued a “Policy Statement
Regarding Inappropriate Business Practices in Long-Term Care Pharmacy” which
comments on activities considered to be inappropriate and possibly illegal.  Among the
activities falling into this category, according to the ASCP, is “offering or providing a
health facility consultant pharmacist services at no charge, below-market value or below
cost in exchange for obtaining or maintaining the business of the facility.  (See Appendix
D)
State anti-kickback laws exist with respect to the Medicaid program in nearly
every state, according to Arthur Lerner.  These laws largely mirror the federal law.  In
addition, more states are beginning to enact anti-kickback laws with respect to non-
governmental payors.
In Maine, there is no anti-kickback statute.  (see Appendix H for a copy of the
letter from the Department of the Attorney General)
Conflict of Interest
The question has been raised whether there is a conflict of interest when the
providers of pharmacy dispensing are also the providers of consultant pharmacy services
in long-term care facilities.  Commission members felt that it would be unlikely for the
pharmacist to control utilization of medication in a way that benefited the pharmacy, since
the pharmacist does not prescribe the medication.  The pharmacist dispenses orders as
received from the medical practitioners.
Under the federal regulation governing drug-regimen review, 42 CFR §483.60, the
consultant pharmacist is required to notify the facility, nursing staff and physician if there
are any irregularities, such as drug interactions, over-utilization and insufficient lab data to
justify optimal usage of medications.
In general, Commission members felt that many of the questions surrounding
conflict of interest are answered when good standards of practice are adhered to.  Long-
term care pharmacists practice in conformity with federal and state laws and rules.  Some
consultant pharmacists may enjoy a competitive advantage by increasing their knowledge
and skills in this specialty practice by membership and participation in organizations and
associations, such as the American Society of Consultant Pharmacists.  Other pharmacists
may attain certification from national professional organizations as a geriatric pharmacy
practitioner through further study and examination.
Recommendations/Considerations
We recommend that a system of monitoring be put into place to ensure that long-
term care facilities are complying with federal law by entering into appropriate contracts
with consultant pharmacists.  Contracts must provide for proper and adequate
reimbursement for the services of the consultant pharmacist, to guard against
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inappropriate activity under which a pharmacy offers to provide the consulting service for
unreasonably low compensation in order to obtain the dispensing services contract and
make up for the losses through drug costs and filling fees.
We recommend that Maine enact an anti-kickback statute similar to federal law
that prohibits fraudulent business practices.
We do not believe there is a need to develop requirements for the practice of
consultant pharmacy beyond the current federal and state laws and rules.  We urge long-
term care facilities staff and their residents to educate themselves about the qualifications
and services offered by consultant pharmacists and about the potential for improved
outcomes, quality assurance and decreased pharmaceuticals costs from consultant
pharmacists who offer a quality of service above and beyond the minimum requirements.
The Commission supports a market-driven philosophy for the provision of consultant
services and encourages consultant pharmacists to offer the highest quality of services.
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RULES ON DISPENSING OF MEDICATION
· Resolve Issue #3:  Examine the determination of new rules pertaining to
dispensing pharmaceuticals in long-term care facilities, such as minimum
supply, and fees charged for the same medication dispensed in the same month
The Maine Medical Assistance Manual provides rules to ensure that minimum
supplies of medications are dispensed and that fees charged for the medication are
appropriate.  Given the fact that the characteristics and needs of nursing home residents
have changed since adoption of the rules, those rules need to be reexamined and updated.
Nursing home admission criteria were modified several years ago to change the
function of most facilities to care for only severely ill patients and to shift many others to
boarding care facilities.  Consequently, the medication need or usage profile has changed
considerably.  Current Medicaid rules require a minimum supply of 30 days in most cases.
In the Medicare setting, particularly in rehabilitation, patients may stay 2 to 4 days or in
many cases less than 30 days.  To decrease waste and the effort involved in return of
medication, a maximum supply of fewer than 30 days, perhaps 14, might be considered.
If the minimum supply for Medicaid residents were increased, pennies may be
saved at the front end, but dollars would be wasted in the long-run because of the increase
in medications that would have to be destroyed because they become out of date.  USP
guidelines dictate that expiration dating be 25% of the manufacturer’s date on the outside
of the bottle, or 6 months, whichever is less.  The more medication is dispensed, the more
that becomes out of date and is destroyed.  Second, long-term care facilities do not have
the space to store an increased supply of medication.  Finally, pharmacy inventory would
need to be increase to supply the excessive amounts.
Recommendations/Considerations
We recommend that the Department of Human Services periodically review its
guidelines for dispensing medications for a Medicaid resident, with consideration given for
the changing needs of physicians and staff to mange acute-care residents.  Those residents
may have multiple changes in medication therapies over short periods of time.
Pharmacists should be made aware of the current guidelines and any changes to them.
We recommend that long-term care facilities be made aware of problems and
possible solutions to problems relating to minimum supply, and that they work with all
disciplines to ensure that the most reasonable, cost-effective dispensing practices are
offered and maintained.
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VERTICAL INTEGRATION
 AND CONFLICT OF INTEREST
· Resolve Issue #4:  Examine conflict of interest created by concurrent
ownership of long-term care facilities and of pharmacies or other related health
care providers that provide services to residents
To protect federal programs from paying excessive amounts for services and
products, federal law provides that payment may be made only for transactions that are
made at “arm’s length.”  In an attempt to advise the Department of Human Services how
to comply with this requirement, the Maine Attorney General prepared a list of
transactions that should not be considered arm’s length.  As a result of this advice, the
Department does not pay a filling fee for services provided by pharmacies that also own
and provide services to nursing homes (vertically integrated companies).
Commission members felt that, although there may have been problems in the past
with overcharging, the current economic climate justifies the department’s review of the
prohibition against paying a filling fee.  Presently, many pharmacy providers (hospitals,
retailers, etc) have access to buying groups to strengthen their buying power  The
possibility that the factual situation has changed with respect to the purchasing power
among groups .  In the late sixties or early seventies, this was not the case and the state
was instrumental in passing the law to prevent excess profits in vertically integrated
companies.
Recommendations
We recommend that the Department of Human Services review the current
prohibition against paying a filling fee to pharmacies that own and provide services to
nursing homes, to determine whether the current situation justifies a continuation of the
prohibition.
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PRACTICE OF OVER-PRESCRIBING
· Resolve Issue #5:  Examine whether there is a practice of overprescribing in
long-term care facilities
The Commission is concerned about the potential for over-prescribing of
medication, but was unable to determine whether there is such a practice in Maine.  None
of the materials available to the Commission during its brief study revealed evidence of
this practice in Maine.
Concerns about over-prescribing and excessive length of therapy might be reduced
by the use of disease state management and pharmaceutical care guidelines.  These
guidelines could be developed by soliciting input from physicians and others who prescribe
medication, medical directors, administrators, directors of nursing, staff nurses and
consultant pharmacists.  Once developed, the guidelines would be implemented using a
team approach to involve those who write prescriptions, consultant pharmacists and
nurses.
There are several existing examples of geriatric pharmaceutical care guidelines
that are being used in long-term care facilities in other states and Canada.  These were
briefly discussed by the Commission.  It is anticipated that use of such guidelines would
enhance the ability of health care practitioners to provide quality care, while reducing
costs, much as the use of drug management has in hospital settings.
It was also suggested that the use of guidelines might allow drug-regimen reviews
to be performed prospectively, e.g., at the time of admission, by an internal consultant
pharmacist and followed up by an external consultant pharmacist at the facility.  For
pharmacies employing this service, efficiencies and improved outcomes could result.
Recommendations/Considerations
We recommend the development of pharmaceutical care guidelines for geriatric
residents in long-term care facilities.  Once developed, these guidelines would offer
geriatric-focused clinical information, assist in providing appropriate pharmaceutical care,
and recommend acceptable and unacceptable drug products by clinical indication.  Such
guidelines can be a valuable tool in enhancing the quality of care and improving outcomes
while providing more cost-effective drug therapy.
STOCKING PATTERNS FOR
STANDARD, NONCHARGEABLE MEDICAL SUPPLIES
· Resolve Issue #6:  Examine whether there are potential cost savings and other
benefits from more efficient patterns for stocking standard, nonchargeable
medical supplies
Standard, nonchargeable medical supplies are those supplies not paid for separately
by Medicaid.  These “house stock” items are expected to be covered under the per diem
rate of reimbursement to the nursing home.  The Medical Assistance Manual lists the
categories of items that are considered house stock, including laxatives, aspirin, cough and
cold syrups, etc.   (See Appendix I)  Medicaid residents must receive these items at no
charge.
Most facilities also have a list of “standing order” items.  These items are selected
products from several categories, e.g. pain medications, laxatives, antacids, that the facility
may also provide to private paying patients without charge, although they are not required
to do so.  Private paying residents have freedom of choice to obtain these supplies from a
pharmacy of their choice.  Although these residents are informed of this right, they often
do not exercise it.
Recommendations/Considerations
The requirement to provide house stock items is an issue that must be enforced on
the nursing home level.  Long-term care pharmacy providers should be aware that these
items are not billable to Medicaid residents.  Private paying residents should be reminded
of their right to purchase these items from a pharmacy of their choice.
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